Genetic Signatures (ASX:GSS) Interest Expense : A$0.00 Mil (TTM As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Genetic Signatures Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Genetic Signatures's interest expense for the six months ended in Dec. 2023 was A$ 0.00 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2023 was A$0.00 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Genetic Signatures's Operating Income for the six months ended in Dec. 2023 was A$ -12.10 Mil. Genetic Signatures's Interest Expense for the six months ended in Dec. 2023 was A$ 0.00 Mil. Genetic Signatures has no long-term debt ⁽¹⁾. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

(1) Note: An indication of "no long-term debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

Genetic Signatures Interest Expense Historical Data

The historical data trend for Genetic Signatures's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genetic Signatures Interest Expense Chart

Genetic Signatures Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Interest Expense

Get a 7-Day Free Trial

-0.03

-0.04

-0.02

Genetic Signatures Semi-Annual Data
	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Interest Expense	Get a 7-Day Free Trial													-0.01	-0.01	-	-	-

Genetic Signatures Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$0.00 Mil.

Genetic Signatures (ASX:GSS) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Genetic Signatures's Interest Expense for the six months ended in Dec. 2023 was A$0.00 Mil. Its Operating Income for the six months ended in Dec. 2023 was A$-12.10 Mil. And its Long-Term Debt & Capital Lease Obligation for the six months ended in Dec. 2023 was A$0.00 Mil.

Genetic Signatures's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

Genetic Signatures had no long-term debt ⁽¹⁾.

The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies' interest coverage to be at least 5. Genetic Signatures Ltd has enough cash to cover all of its debt. Its financial situation is stable.

Genetic Signatures (ASX:GSS) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Genetic Signatures Ltd (ASX:GSS) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

7 Eliza Street, Newtown, Sydney, NSW, AUS, 2042

Website

https://www.geneticsignatures.com

Genetic Signatures Ltd proprietary PCR solutions and automated workflows routinely screen for multiple infectious diseases in a single test. Rapid and accurate results facilitate improved patient management and healthcare outcomes. GSS continues to expand its global reach with direct representation in Australia, Europe, and the United States, and growing distribution partnerships. The company operates under one business segment which is the research and commercialisation of identifying individual genetic signatures to diagnose diseases and disabilities.